Chamaeleo Pharma Names Han Van ‘t Klooster VP of Commercial Operations

Chamaeleo Pharma NV, a Belgium-based oncology company, has named Han Van ‘t Klooster as vice president of commercial operations. He will be a member of Chamaeleo’s management team and will be responsible for the market access and commercial launch of the company’s lead product Fosfestrol for the treatment of advanced prostate cancer.

Mr. Van ‘t Klooster has over 20 years of business experience in the pharmaceutical industry. Prior to joining Chamaeleo, he was the general manager of Pharmion Europe, acquired by Celgene. Before Pharmion, he was the international marketing director oncology at Chiron Corporation—acquired by Novartis—where he was responsible for the commercialization of two oncology products. Mr. Van ‘t Klooster started his career at AstraZeneca as a product manager.